Human Investing LLC cut its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 19.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 32,602 shares of the biopharmaceutical company’s stock after selling 8,082 shares during the period. Human Investing LLC’s holdings in Pfizer were worth $1,671,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in PFE. Lam Group Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth $25,000. Karp Capital Management Corp purchased a new stake in Pfizer during the third quarter valued at about $27,000. Worth Asset Management LLC acquired a new stake in Pfizer during the first quarter worth about $29,000. My Personal CFO LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $32,000. Finally, Delos Wealth Advisors LLC increased its position in Pfizer by 100.0% during the 3rd quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Pfizer Price Performance
Shares of PFE stock opened at $41.50 on Monday. The firm has a fifty day moving average of $41.66 and a two-hundred day moving average of $45.47. The firm has a market cap of $234.24 billion, a P/E ratio of 7.57, a P/E/G ratio of 1.40 and a beta of 0.64. Pfizer Inc. has a 1-year low of $39.23 and a 1-year high of $56.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00.
Insider Activity at Pfizer
In other Pfizer news, major shareholder Pfizer Inc acquired 1,811,594 shares of the firm’s stock in a transaction on Friday, March 17th. The stock was purchased at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the completion of the acquisition, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.05% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, March 17th. SVB Leerink decreased their price target on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a research report on Wednesday, February 1st. Atlantic Securities cut their price objective on Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on Pfizer in a research report on Tuesday, February 7th. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 target price on the stock in a report on Tuesday, February 7th. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $49.93.
About Pfizer
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
